Detailed info

Objectives

SCAPE-1

  • Objective 1 : to describe care experiences of people affected by one of the six most common cancers in Switzerland (i.e. breast, prostate, lung, colon, skin, or blood cancer) treated or followed in four hospitals in the French-speaking Switzerland
  • Objective 2 : to explore the variation of care experiences according to the type of cancer
  • Objective 3 : to validate the questionnaire in French

SCAPE-2

  • Objective 1 : to describe care experiences of cancer patients (all types) treated or followed up in eight hospitals in the French and German-speaking Switzerland
  • Objective 2 : to assess the feasibility of a national survey
  • Objective 3 : to explore the variation of care experiences according to language region, hospital and type of cancer
  • Objective 4 : to validate the questionnaire in French and German

SCAPE-CH

  • Objective 1 : to describe care experiences of people with cancer (all types) treated or followed up in twenty-one oncology centers in the French, German and Italian-speaking Switzerland
  • Objective 2 : to have a complete view of the quality of cancer care in Switzerland
  • Objective 3 : to validate the questionnaire in Italian
  • Objective 4 : to stimulate the development of continuous quality improvement initiatives in cancer care

Key dates of surveys

SCAPE-1

  • October 2018 : Mailing of questionnaire to patients' home
  • January 2019 : Mailing of reminder 
  • April - September 2019 : Analysis and report writing
  • October 2019 : Presentation of results to hospitals
  • May 2020 : Publication of public results on the website; results sent to participants

SCAPE-2 

  • September 2021 : Mailing of questionnaire to patients' home
  • End of October 2021 : Mailing of reminders 
  • January - June 2022 : Analysis and report writing
  • July 2022 : Results sent to hospitals
  • January 2023 : Publication of public results on the website ; results sent to participants

SCAPE-CH

  • September 2023 : Mailing of questionnaire to patients' home
  • End of October 2023 : Mailing of reminders 
  • February - June 2024 : Analysis and report writing
  • July 2024 : Publication of public results on the website; results sent to participating centers

Eligible participants

SCAPE-1 

  • Adult (≥18 years old);
  • Confirmed diagnosis of breast, prostate, lung, colon, skin, or blood cancer;
  • Admitted to or seen at one of the participating hospitals as an outpatient or inpatient;
  • For cancer-related treatment, care, or follow-up;
  • Between the dates of January 1 and June 30, 2018.

SCAPE-2 

  • Adult (≥18 years old);
  • Confirmed diagnosis of cancer (any type);
  • Admitted to or seen at one of the participating hospitals as an outpatient or inpatient;
  • For cancer-related treatment, care, or follow-up;
  • Between the dates of January 1 and June 30, 2021.

SCAPE-CH 

  • Adult (≥18 years old) ;
  • Confirmed diagnosis of cancer (any type);
  • Admitted to or seen at one of the participating oncology centers as an outpatient or inpatient;
  • For cancer-related treatment, care, or follow-up;
  • Between the dates of January 1 and June 30, 2023.

How to participate in the surveys?

Eligible individuals receive at home an envelope with the invitation letter, the information sheet, the paper questionnaire and a pre-stamped return envelope. The invitation letter contains the ID number and the code needed to complete the questionnaire online. 

Questionnaire

The SCAPE-1, SCAPE-2 and SCAPE-CH surveys use the French translation of the English questionnaire « NHS Cancer Patient Experience Survey » adapted to the Swiss context. The questionnaire includes questions on what happened before the diagnosis, diagnostic tests, announcement of diagnosis, treatment decisions, care experiences in hospital as an outpatient and during hospitalization (including cancer operations, radiotherapy and chemotherapy), care and support at home, and follow-up after treatment. It also includes a question about the overall satisfaction and a space for free-text comments. The questionnaire finishes with a few questions about health and personal information such as gender and age.

The SCAPE-2 survey also included specific questions about the impact of the COVID-19 pandemic on cancer care.

The SCAPE-CH survey uses a shorter version of the questionnaire.


Confidentiality

To ensure confidentiality of data, a coding procedure was implemented. The coding means that the personal information (name, address, date of birth, patient number) is replaced by a 5-digit "code." The data collected with the questionnaire contains this code; it does not contain a name or address. The key to the code (the link between the personal data and the code) is kept in a password-protected document only accessible to the local coordinator of the participating oncology center. The questionnaire data is then deidentified (i.e. the document with the key code is destroyed) after the data collection phase. It is then impossible to link answers to a name.

We comply with all data protection guidelines. All surveys are carried out in accordance with the requirements of the Swiss law. The competent cantonal ethics commission has controlled and approved the SCAPE-1, SCAPE-2 and SCAPE-CH surveys.

Results

SCAPE-1: Of the 7’145 patients invited to participate in the survey, 3’121 completed and returned the questionnaire (44% participation rate).

Overall, patient experiences of care were positive with respect to diagnostic tests, contacts with the nurse specialist, operations, and care received during hospitalization and outpatient treatment. Experiences were less positive with regard to written information received at diagnosis, information on side-effects of treatment, psychosocial and financial impacts of cancer, support after treatment and loved ones’ involvement.

SCAPE-2: Of the 6’873 patients invited to participate in the survey, 3’220 completed and returned the questionnaire (47% participation rate).

Overall, experiences of care with diagnostic tests were positive, particularly the waiting time between the prescription of an examination and its completion, the usefulness of the tests performed, the trust in hospital staff and the fact that care was provided with respect and dignity. The experience is less positive with respect to information received at diagnosis, support for short- and long-term side effects of treatment and cancer, information about the impact of cancer on daily activities, difficulty finding a staff member to talk about concerns and fears, financial aspects of the disease, and loved ones’ involvement.


Publications

Arditi, C., Eicher, M., Colomer‐Lahiguera, S., Bienvenu, C., Anchisi, S., Betticher, D., Dietrich, P., Duchosal, M. A., Peters, S., & Peytremann‐Bridevaux, I. (2022). Patients’ experiences with cancer care in Switzerland : Results of a multicentre cross‐sectional survey. European Journal Of Cancer Care, 31(6). https://doi.org/10.1111/ecc.13705  (Link to article)

Arditi, C., Eicher, M., Junod, J., & Peytremann‐Bridevaux, I. (2023). Socio-demographic and health-related determinants of patients’ overall rating and experiences of cancer care. BMC Cancer, 23(1). https://doi.org/10.1186/s12885-023-11445-6 (Link to article)

Arditi, C., Eicher, M., Peytremann-Bridevaux, I., Berrut, S., & Rezzonico, V. (2024). Les enquêtes SCAPE en Suisse. Recueillir l’opinion des patient∙es : pourquoi et comment ? Soins en Oncologie. Journal professionnel de Soins en Oncologie Suisse, 1/2024, 30-33. https://serval.unil.ch/fr/notice/serval:BIB_C19FCBA446B2

Arditi, C., Walther, D., Gilles, I., Lesage, S., Griesser, A., Bienvenu, C., Eicher, M., & Peytremann‐Bridevaux, I. (2020). Computer-assisted textual analysis of free-text comments in the Swiss Cancer Patient Experiences (SCAPE) survey. BMC Health Services Research, 20(1). https://doi.org/10.1186/s12913-020-05873-4 (Link to article)

Jolidon, V., Eicher, M., Peytremann-Bridevaux, I., & Arditi, C. (2024). Inequalities in patients' experiences with cancer care: the role of economic and health literacy determinants. BMC health services research, 24(1), 733. https://doi.org/10.1186/s12913-024-11174-x (Link to article)


Funding

SCAPE-1 and SCAPE-2 were funded by the Swiss Cancer Research.

SCAPE-CH is partially funded by the Federal Commission for Quality (CFQ) and partially by the participating centers.

We use cookies to improve your experience on our site. By continuing to browse, you agree to our use of cookies.